Semax: The Russian Nootropic Peptide for Focus, Stress & Brain Recovery

Semax is a synthetic seven-amino-acid peptide developed in Russia, where it is an approved prescription medicine used for stroke recovery, cognitive complaints, and optic-nerve conditions, and where the biohacking world now reaches for it as a focus-and-resilience nootropic, often topping lists of the best peptides for focus and cognition. The twist that makes Semax unusual among research peptides is that split: it is a real, registered drug in one country and an unapproved "research chemical" everywhere else, with a human evidence base written almost entirely in Russian.

If you have seen Semax marketed for laser focus, mental stamina, or "brain recovery," this guide is the high-level map of the whole compound. We cover what it actually is, how its proposed BDNF-and-NGF mechanism works, what it is studied and used for, the intranasal and subcutaneous forms, the doses people report, side effects, the honest evidence picture, and that two-tier legal status. Each section is a clear overview; the deep-dive topics point to dedicated guides so this page stays a clean hub. Semax is often confused with its calmer Russian cousin, Selank, so we draw a sharp line between the two.

Key Takeaways

• Semax is a synthetic heptapeptide (sequence Met-Glu-His-Phe-Pro-Gly-Pro) and an analog of the ACTH(4-10) fragment of adrenocorticotropic hormone; it was designed to keep the brain-active effects without ACTH's hormonal ones (Wikipedia, "Semax", retrieved 2026-06-15).
• It is approved in Russia but not by the FDA. Semax has been on the Russian List of Vital and Essential Drugs since a government order dated 7 December 2011, yet in the US it is "not FDA approved" and sold only for research use (Wikipedia, "Semax", retrieved 2026-06-15).
• The proposed mechanism centers on neurotrophins. In animal models Semax rapidly raises brain-derived neurotrophic factor (BDNF) and influences nerve growth factor (NGF), and it activates serotonergic and dopaminergic brain systems (Wikipedia, "Semax", retrieved 2026-06-15).
• It is usually given intranasally. Because the peptide is poorly absorbed by mouth, Russian formulations are 0.1% and 1% nasal drops/sprays; subcutaneous injection is the other reported route (Wikipedia, "Semax", retrieved 2026-06-15).
• Most human evidence is Russian and limited by Western standards. Clinical use for stroke, transient ischemic attack, and cognitive disorders is established in Russia, but large Western-standard randomized trials are lacking (Cognitive Vitality / Alzheimer's Drug Discovery Foundation, 2023).
• Semax is not Selank. Both are Russian peptides, but Semax (an ACTH analog) is the cognitive/neuroprotective one, while Selank (a tuftsin analog) is the calming/anxiolytic one (Wikipedia, "Semax", retrieved 2026-06-15).

What is Semax?

Semax is a lab-made peptide of seven amino acids, modeled on a small fragment of the stress hormone ACTH, and developed in Russia as a nootropic and neuroprotective drug. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro (often written MEHFPGP), and it is described as an analog of the ACTH(4-10) fragment. It is studied and used mostly for cognition, focus, stress resilience, and recovery after brain injury.

Chemically, Semax takes the brain-active middle piece of adrenocorticotropic hormone, ACTH(4-7), and bolts on a Pro-Gly-Pro "tail" that protects the peptide from being broken down too quickly, which is why the same molecule is sometimes called an ACTH(4-7) Pro-Gly-Pro peptide and sometimes an ACTH(4-10) analog. They are the same compound. The design goal was to keep ACTH's effects on attention, memory, and neuroprotection while dropping its hormonal (cortisol-releasing) activity. If injectable or intranasal peptides are new to you, start with our how peptides work guide.

The single most important fact about Semax is its two-tier status. In Russia it is an approved, prescribed medicine; in the United States and most of the world it is an unapproved drug with no regulatory review, sold as a "research use only" chemical. Everything else in this guide should be read through that lens.

Citation capsule. Semax is a synthetic heptapeptide (sequence Met-Glu-His-Phe-Pro-Gly-Pro / MEHFPGP) and an analog of the ACTH(4-10) fragment of adrenocorticotropic hormone, developed in Russia as a nootropic and neuroprotective agent. It is on the Russian List of Vital and Essential Drugs but is not FDA-approved. Source: Wikipedia, "Semax," 2026; CAS 80714-61-0; PubChem CID 122178; molecular formula C37H51N9O10S.

How does Semax work?

Semax is thought to work mainly by raising neurotrophins, the brain's own growth factors, especially BDNF and NGF, which support the survival, plasticity, and repair of neurons, while also nudging the dopamine and serotonin systems that govern focus and mood. In plain terms, it appears to help the brain protect and rewire itself. Crucially, this picture comes mostly from animal and cell studies, not large human trials.

The leading idea is that Semax acts as a signal that tells brain tissue to ramp up its own maintenance crew. According to Wikipedia's summary of the research, in animal models Semax "rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF)" and activates "serotonergic and dopaminergic brain systems," with possible interaction at melanocortin receptors and inhibition of enzymes that break down the body's natural enkephalins (Wikipedia, "Semax", retrieved 2026-06-15). The neurotrophin angle is the one most often highlighted, because BDNF and NGF are central to learning, memory, and recovery after injury.

Here is what each proposed mechanism contributes, in simple terms:

• BDNF (brain-derived neurotrophic factor): Semax is reported to quickly raise BDNF and its receptor signaling in regions like the hippocampus, supporting neuron survival and plasticity. This is the most cited mechanism.
• NGF (nerve growth factor): changes in NGF and BDNF gene expression have been described together, pointing to a broad neurotrophin effect rather than a single switch.
• Dopamine and serotonin systems: activation of these networks is the likely route to the reported focus, motivation, and mood effects.
• Neuroprotection: by combining neurotrophin support with effects on inflammation and blood flow in injury models, Semax is studied as a way to protect brain tissue under stress (for example, after a stroke).

The receptor-and-signaling deep dive (exactly how a peptide changes neurotrophin gene expression) is its own topic. We keep it at overview level here and link out to how peptides work for the foundations.

What is Semax used for?

In Russia, Semax is an approved medicine for stroke and transient ischemic attack, memory and cognitive disorders, and optic-nerve disease, and it is also used to support the immune system; outside Russia, biohackers use it off-label for focus, mental stamina, and stress resilience. None of these are FDA-approved uses. The clinical indications come from Russian practice; the nootropic uses are community-driven.

The headline clinical use is acute brain protection. In Russia, Semax is given in the hospital setting for ischemic stroke and transient ischemic attack, where the goal is to limit damage and support recovery, and it is also prescribed for cognitive and memory complaints and for optic-nerve conditions (Wikipedia, "Semax", retrieved 2026-06-15). Outside that system, the dominant use is as a nootropic: people report taking it for sharper focus, mental endurance during demanding work, and a steadier response to stress, which lines up with its dopamine, serotonin, and BDNF effects.

A quick overview of the areas Semax is studied or used for, and where the evidence stands:

Because several of these are distinct future spokes, we keep them brief here. The honest headline: Semax has a genuine clinical track record in Russia, but the Western-standard evidence that would confirm those uses elsewhere has not been built.

How strong is the evidence for Semax?

The evidence for Semax is real but lopsided: a substantial Russian clinical and research literature, plus solid animal mechanism data, set against very few large trials that meet Western regulatory standards. That is why it can be an approved drug in one country and an unproven research chemical in another at the same time.

The most important nuance is where the data come from. Semax has decades of use and study in Russia, including clinical use for stroke and cognitive disorders, but much of that literature is published in Russian, often in smaller or observational studies, and has not been replicated in the large, double-blind, placebo-controlled randomized trials that regulators like the FDA require. A research-oriented review by the Alzheimer's Drug Discovery Foundation notes that the human evidence is dominated by Russian-origin studies of limited scale and design, and treats Semax as promising but not established by Western standards (Cognitive Vitality / Alzheimer's Drug Discovery Foundation, 2023, retrieved 2026-06-15).

Why the evidence looks different in Russia vs. the West

It helps to separate two honest truths that both apply to Semax. The first is that it is not vaporware: it has been an approved, prescribed medicine in Russia for years, it sits on that country's essential-drugs list, and there is a real body of mechanistic work showing it raises BDNF and engages dopamine and serotonin systems in animals (Wikipedia, "Semax", retrieved 2026-06-15). The second is that this is not the same as Western proof: most of the human work is regional, language-siloed, and methodologically lighter than what the FDA or EMA would demand, so agencies outside Russia have simply never evaluated it. Neither truth cancels the other.

For a reader, the practical takeaway is to calibrate expectations to that gap. Semax is more clinically grounded than a typical "research chemical," because a national regulator has approved it and clinicians use it. But "approved in Russia" is not "proven to the standard the rest of the world uses," and the focus-and-stamina nootropic claims in particular rest heavily on mechanism and anecdote rather than large controlled trials. Anyone weighing Semax is doing so without the Western regulatory safety net that an FDA-approved drug provides.

Our take: The most common mistake we see is collapsing Semax into one of two cartoons, either "miracle Russian brain drug" or "unproven scam." Both are wrong. The accurate read is a genuinely interesting, Russia-approved peptide with a real but region-specific and Western-light evidence base. Hold both halves at once.

What forms of Semax are there, and how is it taken?

Semax is most often used intranasally, as nasal drops or spray, because the peptide is poorly absorbed if swallowed; subcutaneous injection is the other reported route, and Russian products come as 0.1% and 1% solutions. The form matters more for Semax than for many peptides, because the nose is the practical delivery path to the brain.

Like other peptides, Semax is broken down in the gut, so oral tablets are not a reliable way to take it. The standard Russian medicinal forms are intranasal solutions at two strengths, a 0.1% solution for general nootropic and milder uses and a stronger 1% solution for clinical situations such as stroke, both dosed as drops into the nostrils (Wikipedia, "Semax", retrieved 2026-06-15). In the research-chemical market outside Russia, Semax is also sold as a lyophilized powder that buyers reconstitute and use intranasally or by subcutaneous injection.

For orientation only, here is how the two main routes compare (this is descriptive, not a recommendation):

The detailed reconstitution math, drop counting, and storage handling are a dedicated topic. We keep it at overview level here and link out to how to vet peptide quality for sourcing and to how peptides work for the basics. Note that the intranasal habit shows up clearly in our own tracking data, which we cover below.

What doses of Semax do people report using?

There is no FDA-validated dose for Semax, but Russian practice and community protocols cluster around intranasal use of the 0.1% solution for nootropic goals and the 1% solution for clinical situations, with reported daily amounts ranging from a few hundred micrograms up to several thousand micrograms in short courses. These are reported figures, framed honestly as Russian practice or community convention, not an established or recommended dose.

The most commonly described pattern is intranasal dosing split across the day, using the 0.1% solution for focus and general use and reserving the stronger 1% solution for acute clinical settings like stroke. Reported research and clinical courses have used intranasal totals in the hundreds of micrograms up to around 6,000 mcg per day given over short courses of roughly 10 days, particularly in the higher-dose neurological context (Cognitive Vitality / Alzheimer's Drug Discovery Foundation, 2023, retrieved 2026-06-15). We label all of this as a reported convention because the FDA has never reviewed a Semax dose and the Western-standard pharmacology is thin. For the reconstitution and mcg-to-units math if you choose to calculate from these figures, see the Semax dosage calculator.

Our take: It is tempting to treat "0.1% nasal drops, twice a day" as if it were a settled regimen because Russian products are labeled that way. Remember the framing: those labels reflect Russian regulatory decisions and practice, not a dose that the FDA or EMA has reviewed. For everyone outside that system, they are reported conventions, not a prescription.

What are the side effects of Semax?

Semax is generally described as well tolerated at the doses used in Russian practice, with the most common issue being mild nasal irritation from the intranasal drops; because Western-standard long-term safety data are limited, the honest headline is that its full safety profile is not fully characterized. "Usually well tolerated in reported use" is not the same as "proven safe long-term."

In its Russian clinical history and the available studies, Semax has a reassuring short-term tolerability record, and the intranasal route avoids injection-related risks. The most frequently reported effect is local irritation in the nose from the drops or spray. Because Semax also touches the dopamine and serotonin systems, occasional changes in alertness, sleep, or mood are plausible, though these are not well quantified in controlled data (Cognitive Vitality / Alzheimer's Drug Discovery Foundation, 2023, retrieved 2026-06-15).

A hub-level overview of what is reported and what is uncertain:

• Commonly reported (mild): nasal irritation, dryness, or a brief stinging sensation from intranasal use.
• Possible (neurotransmitter-linked): changes in alertness, sleep, or mood, given the dopamine and serotonin activity (anecdotal, not well quantified).
• Quality-related risks: in the research-chemical market outside Russia, contamination, mislabeled potency, or impurities are real concerns independent of the peptide itself.
• Not well characterized: long-term safety by Western-standard monitoring, because that long-horizon controlled data largely does not exist outside Russia.

This is the hub-level summary; the full breakdown lives in our Semax side effects deep-dive. For sourcing and how to reduce quality-related risk, see how to vet peptide quality.

How does Semax compare to Selank?

Semax and Selank are both Russian heptapeptides used as nootropics, but they pull in different directions: Semax (an ACTH analog) is the cognitive, focus, and neuroprotection peptide, while Selank (a tuftsin analog) is the calming, anti-anxiety peptide. They are frequently confused, and sometimes used together, but they are not interchangeable.

The cleanest way to hold the two apart is origin and purpose. Semax is built from a fragment of the stress hormone ACTH and is registered in Russia as a nootropic and neuroprotective drug, leaning on BDNF, NGF, dopamine, and serotonin to support attention and brain recovery. Selank is built from tuftsin, a small immune-active peptide, and is registered in Russia as an anxiolytic, leaning on calming, anti-anxiety effects (Wikipedia, "Semax", retrieved 2026-06-15). So at a high level: reach toward Semax for focus, drive, and recovery; reach toward Selank for calm and anxiety relief.

That is the hub-level contrast, and it is deliberately brief. The full comparison, including Selank's tuftsin mechanism, its anxiolytic evidence, the stacking rationale, and which one people choose for which goal, lives in its own article. We keep it short here to avoid overlapping that piece: see our dedicated Selank guide and the side-by-side Semax vs Selank comparison.

Is Semax safe and legal?

Semax has a split legal status: it is an approved, prescribed medicine in Russia, but it is not approved by the FDA or most other regulators, so outside Russia it is an unapproved drug, and the products sold online are unapproved "research chemicals." That two-tier status is the single most important practical fact about it.

On legality, the contrast is stark. In Russia, Semax is a registered drug on the List of Vital and Essential Drugs, approved by government order dated 7 December 2011, and is prescribed by clinicians (Wikipedia, "Semax", retrieved 2026-06-15). In the United States it is "not FDA approved" and is unscheduled, meaning it has not been evaluated or approved for any medical use; vendors sell it labeled "for research use only, not for human consumption," which is the same gray-market posture as other unapproved peptides (Wikipedia, "Semax", retrieved 2026-06-15). It has also not been evaluated or marketed in most other countries.

A note for athletes: Semax is not listed on the World Anti-Doping Agency Prohibited List by name, but as an ACTH-fragment analog it could plausibly fall under WADA's broader prohibition on corticotrophins and related substances (class S2) or on non-approved substances (class S0), so competitive athletes should treat it with caution and check the current list rather than assume it is allowed (World Anti-Doping Agency, Prohibited List, retrieved 2026-06-15). For the full legal picture and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: The single most common misunderstanding is reasoning "it's an approved drug in Russia, so it must be fine to buy and use here." Russian approval is real, but it does not transfer. In the US it is an unapproved drug sold for research use only, with no FDA review of its safety or quality. Approved-somewhere is not approved-here.

How do people obtain Semax?

Outside Russia, most people access Semax by buying unapproved "research chemical" intranasal solutions or lyophilized powder online, which is a legal and safety gray market; inside Russia it is obtained as a prescription medicine. There is no legitimate "get a prescription" route for an unapproved drug in countries where it is not approved, outside of a clinical trial.

For readers outside Russia, the research-peptide market is where most searches end up: vendors sell Semax "for research use only," and buyers use it off-label intranasally or by injection. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulatory oversight of what is actually in the vial.

If you are researching that path despite the risks, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your own country and situation, including sport and workplace rules. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it for identity and purity. See how to vet peptide quality.
3. Understand handling before anything else. Reconstitution, sterile intranasal use, and cold storage are not optional. See how peptides work.
4. Talk to a qualified clinician who can weigh your specific health situation, medications, and contraindications, especially given Semax's effects on dopamine and serotonin.

We are describing what people do, not endorsing it. Using an unapproved drug means accepting unknown risks with no regulatory safety net.

Frequently Asked Questions

The bottom line

Semax is one of the more interesting compounds in the peptide world precisely because it refuses to fit the usual story. It is not a pure research chemical with nothing behind it, and it is not an FDA-blessed medicine either. It is a real, Russia-approved drug, on that country's essential-medicines list, with a coherent neurotrophin-based mechanism and a genuine clinical track record for stroke, cognition, and optic-nerve conditions. That is why the focus-and-recovery reputation exists.

The other half of the story is discipline. Most of the human evidence is Russian-language, regional, and lighter than Western trial standards; the FDA and most other regulators have never reviewed it; and outside Russia it is sold as an unapproved research chemical with no guarantee of what is in the vial. Keep Semax distinct from its calmer cousin Selank, hold the "approved in Russia but unproven by Western standards" framing in both hands, and treat any decision as one made without a regulatory safety net. From here, the natural next reads are Selank, how to vet peptide quality, and are peptides legal.

Sources

• Wikipedia. "Semax." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Semax
• PubChem (National Library of Medicine). "Semax, CID 122178." Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/122178
• Cognitive Vitality / Alzheimer's Drug Discovery Foundation. "Semax — For Researchers." 2023. Retrieved 2026-06-15. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf
• Dolotov, O.V., et al. "Semax, an analog of ACTH(4-10), regulates expression of BDNF and trkB in the rat hippocampus." Brain Research / ScienceDirect, 2006. Retrieved 2026-06-15. https://www.sciencedirect.com/science/article/abs/pii/S0006899306022955
• "NGF and BDNF gene expression in rat hippocampus under the action of Semax." PubMed, 2009. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/19662538/
• "Semax activates dopaminergic and serotoninergic brain systems." PubMed, 2006. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/16362768/
• World Anti-Doping Agency / USADA. "Prohibited List." Retrieved 2026-06-15. https://www.usada.org/substances/prohibited-list/
• Innerbody Research. "Semax Peptide: Benefits, Dosage, and Safety." Updated 2026. Retrieved 2026-06-15. https://www.innerbody.com/semax-peptide